Roche Shakes Up R&D, Closes Nutley Operations
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche will shut down its Nutley, N.J., pharma operations – once its U.S. headquarters – by the end of 2013 in a cost-saving measure that will leave only a small group of employees on the East Coast.
You may also be interested in...
Roche Reviews Its Research Priorities With Opening Of Translational Research Center
Oncology may consume a disproportionate percentage of Roche’s R&D budget and generate the bulk of its revenues, but at a day-long symposium celebrating the opening of Roche’s new translational research center in NYC, the company’s scientific leaders highlighted its priorities in other complex diseases.
Roche Opens NY R&D Hub As Its pRED Head Vows To Boost Alliances
Amid a day of celebrations around the long-awaited opening of its translational and clinical research center in New York, Roche’s new head of research and early development, the superstar scientist John Reed, offered a glimpse of how the organization is restructuring its external relationships and its priorities going forward.
Roche CEO Severin Schwan: Fueled By Innovation, Emerging Markets
Roche’s CEO Severin Schwan says the Swiss group’s recent revamps, lack of patent expiries, and ongoing drug innovations give the world’s largest maker of cancer drugs a strong position to expand its sales globally, helped by new cutting-edge therapies and creative business approaches.